REVIEW PAPER
IgG4-related diseases - a new look in rheumatology
More details
Hide details
Submission date: 2013-01-21
Final revision date: 2013-05-27
Acceptance date: 2013-07-26
Online publication date: 2013-09-11
Publication date: 2013-08-30
Reumatologia 2013;51(4):284-292
KEYWORDS
TOPICS
ABSTRACT
IgG4-related diseases are characterised by tissue infiltration of IgG4-positive plasma cells and diffuse or localised fibrosis. Elevated serum IgG4 is also present. With time the subsequent organs are affected; thus high levels of IgG and IgG4 should prone to systematic control to prevent multiorgan dysfunction. Detailed diagnostics is necessary and should include radiologic, ultrasonographic and tomographic evaluation, measurements of serum IgG4 and laboratory parameters specific to dysfunction of the affected organ. An isolated infiltration by IgG4+ plasmocytes or elevated IgG4/IgG ratio constitutes relatively non-specific findings. Thus, during diagnostics the combined presence of the characteristic histopathological appearance, increased numbers of IgG4+ plasma cells, elevated serum IgG4 and organomegaly with progressing organ dysfunction is necessary. Glucocorticosteroids are effective in most cases (at least at the beginning of treatment), but disease flares are common. The effectiveness of biologic therapy is also underlined in the literature.
REFERENCES (37)
1.
Hamano H, Kawa S, Horiuchi A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. New Engl J Med 2001; 344: 732-738.
2.
Kamisawa T, Funata N, Hayashi Y, et al. A new clinicopathological entity of IgG4-related autoimmune disease. J Gastroenterol 2003; 38: 982-984.
3.
Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. The American J Gastroenterol 2003; 98: 2811-2812.
4.
Umehara H, Okazaki K, Masaki Y, et al. A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 2012; 22: 1-14.
5.
Guma M, Firestein GS. IgG4-related diseases. Best Pract Res Clin Rheum 2012; 26: 425-438.
6.
Saeki T, Saito A, Hiura T, et al. Lymphoplasmacytic infiltration of multiple organs with immunoreactivity for IgG4: IgG4-related systemic disease. Intern Med 2006; 45: 163-167.
7.
Khosroshahi A, Stone JH. IgG4-related systemic disease: the age of discovery. Curr Opin Rheumatol 2011; 23: 72-73.
8.
Smyrk TC. Pathological features of IgG4-related sclerosing disease. Curr Opin Rheumatol 2011; 23: 74-79.
9.
Aalberse RC, Schuurman J. IgG4 breaking the rules. Immunology 2002; 105:9-19.
10.
Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy 2009; 39: 469-477.
11.
Tao MH, Smith RI, Morrison SL. Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. J Exp Med 1993; 178: 661-667.
12.
Rispens T, Ooievaar-De Heer P, Vermeulen E, et al. Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions. J Immunol 2009; 182: 4275-4281. .
13.
Schuurman J, Perdok GJ, Gorter AD, et al. The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds. Mol Immunol 2001; 38: 1-8.
14.
Aucouturier P, Danon F, Daveau M, et al. Measurement of serum IgG4 levels by a competitive immunoenzymatic assay with monoclonal antibodies. J Immunol Methods 1984; 74: 151-162.
15.
Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366: 539-551.
16.
Wakabayashi T, Kawaura Y, Satomura Y, et al. Long-term prognosis of duct-narrowing chronic pancreatitis: strategy for steroid treatment. Pancreas 2005; 30: 31-39.
17.
Okazaki K, Uchida K, Koyabu M, et al. Recent advances in the concept and diagnosis of autoimmune pancreatitis and IgG4-related disease. J Gastroenterol 2011; 46: 277-288.
18.
Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 2012; 22: 21-30.
19.
Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23: 57-66.
20.
Okazaki K, Uchida K, Miyoshi H, et al. Recent concepts of autoimmune pancreatitis and IgG4-related disease. Clin Rev Allerg Immunol 2011; 41: 126-138.
21.
Kawa S, Ito T, Watanabe T, et al. The utility of serum IgG4 concentrations as a biomarker. Int J Rheumatol 2012; 2012: 198314.
22.
Matsubayashi H, Sawai H, Kimura H, et al. Characteristics of autoimmune pancreatitis based on serum IgG4 level. Dig Liver Dis 2011; 43: 731-735.
23.
Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol 2011; 23: 67-71.
24.
Ito T, Nishimori I, Inoue N, et al. Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan. J Gastroenterol 2007; 42 (Suppl. 18): 50-58.
25.
Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-1507.
26.
Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715.
27.
Cheuk W, Yuen HK, Chu SY, et al. Lymphadenopathy of IgG4-related sclerosing disease. Am J Surg Pathol 2008; 32: 671-681.
28.
Sato Y, Kojima M, Takata K, et al. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease. Mod Pathol 2009; 22: 589-599.
29.
Abraham SC, Cruz-Correa M, Argani P, et al. Lymphoplasmacytic chronic cholecystitis and biliary tract disease in patients with lymphoplasmacytic sclerosing pancreatitis. Am J Surg Pathol 2003; 27: 441-451.
30.
Zen Y, Harada K, Sasaki M, et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 2004; 28: 1193-1203.
31.
Li Y, Bai Y, Liu Z, et al. Immunohistochemistry of IgG4 can help subclassify Hashimoto’s autoimmune thyroiditis. Pathol Int 2009; 59: 636-641.
32.
Dahlgren M, Khosroshahi A, Nielsen GP, et al. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken) 2010; 62: 1312-1318.
33.
Kakudo K, Li Y, Taniguchi E, et al. IgG4-related disease of the thyroid glands. Endocr J 2012; 59: 273-281. .
34.
Li Y, Nishihara E, Hirokawa M, et al. Distinct clinical, serological, and sonographic characteristics of hashimoto's thyroiditis based with and without IgG4-positive plasma cells. J Clin Endocrinol Metab 2010; 95: 1309-1317.
35.
Cheuk W, Yuen HK, Chan JK. Chronic sclerosing dacryoadenitis: part of the spectrum of IgG4-related Sclerosing disease? Am J Surg Pathol 2007; 31: 643-645.
36.
Masaki Y, Kurose N, Umehara H. IgG4-related disease: a novel lymphoproliferative disorder discovered and established in Japan in the 21st century. J Clin Exp Hematop 2011; 51: 13-20.
37.
Masaki Y, Dong L, Kurose N, et al. Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009; 68: 1310-1315.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.